Latest News

Filters

Filter by tags: TRIUMF Clear all tag filters

7 news articles found


Canadian research centre TRIUMF and Canadian-German nuclear technology company Dual Fluid have signed a memorandum of understanding (MOU) to advance the development of a small modular reactor (SMR) based on Dual Fluid technology. TRIUMF is Canada’s particle accelerator centre and a leading research centre for subatomic physics.

Date: Friday, 17 March 2023
Original article: neimagazine.com/news/newscanadas-triumf-and-dual-fluid-co-operate-on-smr-development-10679822

Canadian-German nuclear technology company Dual Fluid has signed a memorandum of understanding (MoU) with Canadian research centre TRIUMF to advance the development of a small modular reactor based on Dual Fluid technology.

Date: Tuesday, 14 March 2023
Original article: world-nuclear-news.org/Articles/Dual-Fluid,-TRIUMF-team-up-for-SMR-development

Canadian Nuclear Laboratories (CNL) are to collaborate with particle accelerator centre TRIUMF on nuclear and materials science and technology. A memorandum of understanding (MOU) between CNL and TRIUMF identifies areas of cooperation that includes the delivery of joint research projects and the sharing of scientific information and equipment.

Date: Wednesday, 01 February 2023
Original article: neimagazine.com/news/newscanadas-nuclear-labs-to-collaborate-with-particle-accelerator-centre-10558475

The memorandum of understanding (MoU) between Canadian Nuclear Laboratories (CNL) and the TRIUMF particle accelerator centre aims to foster closer ties between the two nuclear research organisations and leverage their complementary activities as they explore and pursue collaboration opportunities in nuclear and materials science and technology.

Date: Friday, 27 January 2023
Original article: world-nuclear-news.org/Articles/MoU-strengthens-Canadian-nuclear-research

Canada’s particle accelerator centre, TRIUMF, and Canadian Nuclear Laboratories (CNL) have completed the first joint production run of actinium-225, a rare medical isotope that shows great promise as the basis for new, cutting-edge cancer therapies.

Date: Wednesday, 30 October 2019
Original article: neimagazine.com/news/newscanadian-scientists-test-technology-for-production-of-actinium-225-7478484

Canadian Prime Minister Justin Trudeau on 1 November announced funding for construction of the Institute for Advanced Medical Isotopes (IAMI) within the campus of the TRIUMF national particle accelerator at the University of British Columbia in Vancouver. TRIUMF is owned and operated as a joint venture by a consortium of universities. With investment from the Government of Canada, the Province of British Columbia, and contributions from TRIUMF, the BC Cancer Foundation and the University of British Columbia, the construction of the IAMI facility is valued at CAD31.8 million ($24.3m). With additional equipment and philanthropic funding, the total value of the project will be more than CAD50 million. Ottawa is providing $10.2 million, the provincial government $12.2 million, TRIUMF $5.4 million, and the BC Cancer Foundation and UBC $2 million each. Trudeau said: “We know that for our country to lead in an ever-evolving economy and create the jobs of tomorrow, we have to invest in our scientists and in the institutions that support them.”

Date: Monday, 05 November 2018
Original article: neimagazine.com/news/newscanada-announces-funding-for-advanced-medical-isotopes-institute-6835925

TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL) announced on 27 September that they have agreed to pursue a strategic partnership around the commercial production of the medical isotope, Actinium-225, as the basis of new cancer treatments. Actinium-225 is an alpha-emitting isotope with a short half-life that can be combined with a protein or antibody that specifically targets cancer cells.

Date: Tuesday, 02 October 2018
Original article: neimagazine.com/news/newscanadian-laboratories-collaborate-to-produce-actinium-225-6779321